Effects of the CDK-inhibitor CYC202 on p38 MAPK, ERK1/2 and c-myc activities in papillomavirus type 16 E6- and E7-transformed human keratinocytesATANASOVA, Ganka N; ISAEVA, Antonia R; ZHELEV, Nikolai et al.Oncology reports. 2007, Vol 18, Num 4, pp 999-1005, issn 1021-335X, 7 p.Article

Targeting low molecular weight cyclin E (LMW-E) in breast cancerNANOS-WEBB, Angela; JABBOUR, Natalie A; MULTANI, Asha S et al.Breast cancer research and treatment. 2012, Vol 132, Num 2, pp 575-588, issn 0167-6806, 14 p.Article

Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignanciesLE TOURNEAU, Christophe; FAIVRE, Sandrine; GIANELLA-BORRADORI, Athos et al.European journal of cancer (1990). 2010, Vol 46, Num 18, pp 3243-3250, issn 0959-8049, 8 p.Article

2003: des progrès majeurs avec les molécules ciblées = 2003: main progress with targeted moleculesMEDIONI, J; KLOOS, I; RAYMOND, E et al.La Lettre du cancérologue (Boulogne). 2003, Vol 12, Num 6, pp 234-238, issn 1165-113X, 5 p.Article

Small-molecule cyclin-dependent kinase modulatorsSENDEROWICZ, Adrian M.Oncogene (Basingstoke). 2003, Vol 22, Num 42, pp 6609-6620, issn 0950-9232, 12 p.Article

Potential use of pharmacological cyclin-dependent kinase inhibitors as anti-HIV therapeutics : HIV drug designPUMFERY, Anne; DE LA FUENTE, Cynthia; BERRO, Reem et al.Current pharmaceutical design. 2006, Vol 12, Num 16, pp 1949-1961, issn 1381-6128, 13 p.Article

Analysis of cyclin B1 and CDK activity during apoptosis induced by camptothecin treatmentBORGNE, A; VERSTEEGE, I; MAHE, M et al.Oncogene (Basingstoke). 2006, Vol 25, Num 56, pp 7361-7372, issn 0950-9232, 12 p.Article